Authors of an article discuss posters that were presented at the 30th European Academy of Dermatology and Venereology Congress 2021 on fixed-dose calcipotriol and betamethasone dipropionate cream (CAL/BDP cream) based on Poly-Aphron Dispersion Technology. In two randomized, phase 3 trials of adults with plaque psoriasis, CAL/BDP cream was compared with vehicle and an active comparator CAL/BDP gel/topical suspension (TS). Considerable greater efficacy in favor of CAL/BDP was seen for all efficacy endpoints from the pooled data from both trials vs CAL/BDP gel/TS. No drug-related adverse reactions with a frequency greater than 1% were seen, as CAL/BDP cream was found to be well-tolerated and comparable to CAL/BDP gel/TS. In one of the studies, CAL/BDP cream was found to improve quality of life. CAL/BDP cream was also superior to CAL/BDP gel/TS in terms of treatment convenience, as measured by the Psoriasis Treatment Convenience Scale. Another study comparing CAL/BDP cream and CAL/BDP foam found CAL/BDP cream to be statistically superior compared with the foam in four of five areas of treatment satisfaction.
Reference: Pinter A, Gold LS, Reich A, et al. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37 Suppl 1:14-19. doi:10.1111/jdv.18755
